Bayer HealthCare has received the US Food and Drug Administration (FDA) approval for its new blood glucose monitoring (BGM) system, Contour Next EZ.
Contour Next EZ includes meter and test strip sensors as well as the company’ proprietary new blood glucose sensor technology.
The Contour BGM system utilizes proprietary electrochemical mediator and meter algorithm which provides a stable, signal-to-noise ratio that facilitates determination of blood glucose readings, even at low blood glucose levels.
The new technology also ensures that the system remains accurate under various storage conditions, corrects for common errors and is not affected by hematocrit or many common interfering substances in the blood such as acetaminophen, vitamin C.
Bayer said Contour Next EZ system is currently available in other countries as Contour XT.